Published online before print March 15, 2007, doi: 10.1161/ATVBAHA.107.140673
© 2007 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice
From the Department of Anesthesia & Critical Care, Massachusetts General Hospital, Shriners Hospital for Children, Harvard Medical School, Charlestown, Mass.
Correspondence to Dr Masao Kaneki, Department of Anesthesia & Critical Care, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Rm. 6604, Charlestown, MA 02129. E-mail mkaneki{at}partners.org
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— Statins are presumed to exert their antiatherogenic effects in part via lipid-lowering–independent mechanisms. Inhibition of protein farnesylation and/or geranylgeranylation by statins has been postulated to contribute to the lipid-lowering–independent effects. However, a role for protein farnesylation in atherogenesis has not yet been studied. Therefore, we examined the effects of farnesyltransferase inhibitor, manumycin A, on the development of atherosclerosis in apolipoprotein E (apoE)-deficient mice fed a high-fat diet.
Methods and Results— Manumycin A treatment for 22 weeks decreased Ras activity, and reduced fatty streak lesion size at the aortic sinus to 43% of that in vehicle-treated apoE-deficient mice (P<0.05), while plasma total cholesterol was unaltered. Moreover, manumycin A reduced 
-smooth muscle actin-positive area to 29% of that in vehicle-treated apoE-deficient mice (P<0.01). The prevention of atherogenesis by manumycin A was accompanied by amelioration of oxidative stress, as judged by reduced ex vivo superoxide production and nitrotyrosine immunoreactivity.
Conclusions— These results indicate that the inhibition of farnesyltransferase prevents the development of mature atherosclerosis with concomitant alleviation of oxidative stress in apoE-deficient mice. The present data highlight farnesyltransferase as a potential molecular target for preventive and/or therapeutic intervention against atherosclerosis.
Farnesyltransferase inhibitor, manumycin A, prevented the development of atherosclerosis with concomitant decreases in oxidative stress and Ras activation, with unaltered plasma cholesterol level. These results highlight farnesyltransferase as a molecular target to prevent atherogenesis and suggest that inhibition of farnesylation may be involved in lipid-lowering–independent beneficial effects of statins.
Key Words: apoE-deficient mice • atherosclerosis • farnesyltransferase • oxidative stress • Ras
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have had a major impact by decreasing cardiovascular events in humans.1,2 The efficacy of statins has been considered to be primarily explained by their lipid-lowering property. However, a growing body of evidence highlights the lipid-lowering–independent effects of statins.3,4 Rapid onset of clinical benefits and weak correlations between plasma cholesterol levels and coronary lumen change or cardiovascular events indicate an involvement of nonlipid-lowering actions of statins.5–7 In fact, statins exhibited the beneficial effects to increase flow-mediated vasodilation in normocholesterolemic subjects,8–10 as well. Recently, the National Cholesterol Education Project (NCEP) Adult Treatment Panel III guideline recommended that patients with diabetes and cardiovascular disease should initiate statin therapy regardless of baseline low-density lipoprotein cholesterol levels,11 although more evidence is needed to support a universal recommendation of statin therapy for all patients with diabetes and without cardiovascular disease. In animal models of atherosclerosis, lipid-lowering–independent beneficial effects of statins have been shown. Low doses of statins reduce atherogenesis without altering cholesterol level in rabbits fed high-cholesterol diet,12–15 apolipoprotein E (apoE)*3-leiden transgenic mice,16 and allograft atherosclerosis.17
The nonlipid-lowering effects of statins are presumed to be accounted for by direct pleiotropic actions on the vessel wall, which include anti-inflammatory and antioxidant effects of the drugs.18–20 Nevertheless, the molecular mechanisms by which statins exert these pleiotropic actions remain to be determined.
3-Hydroxy-3-methylglutaryl- coenzyme A reductase is the rate-limiting enzyme of cholesterol synthesis. The inhibition of this enzyme results in decreased production of not only cholesterol but also geranyl pyrophosphate and farnesyl pyrophosphate, leading in turn to reduced protein isoprenylation, namely, geranylgeranylation and farnesylation, respectively. Of note, statins inhibit DNA replication and cell cycle progression in many cell types, including vascular smooth muscle cells, independent of the inhibition of cholesterol synthesis. The inhibitory effects of statins on cell proliferation were rescued by the addition of precursors of protein isoprenylation, farnesol, or geranylgeraniol, but not by cholesterol.21 These previous findings suggest that the inhibition of farnesylation or geranylgeranylation may be important for cholesterol-independent pleiotropic effects of statins. Thus, statins have been proposed to exert their nonlipid-lowering effects through the inhibition of isoprenylation.4
Farnesylation is critical for activation of Ras family small G-proteins. A role of Rho family small G-proteins including Rac in atherogenesis has been characterized.22 Rac is activated by geranylgeranylation, but not by farnesylation. However, a role for Ras family small G-proteins or farnesyltransferase in the pathogenesis of atherosclerosis has not been extensively studied. Therefore, to investigate a role for farnesyltransferase in the development of atherosclerosis, we examined the effects of the farnesyltransferase inhibitor, manumycin A, in apoE-deficient mice fed a high-fat diet.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Animals
Male apoE-deficient mice on C57BL/6 background and male wild-type C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Me). The Institutional Animal Care Committee approved the study protocol. The apoE-deficient and wild-type mice were housed in mesh cages in a room maintained at 25°C and illuminated in 12:12-hour light–dark cycles; they were provided with a high-fat diet and water ad libitum. The high-fat diet contained 58.0% calories from fat, 25.6% from carbohydrates, and 16.4% from proteins (D12309; Research Diets, New Brunswick, NJ).
Treatment With Manumycin A
The treatment with farnesyltransferase inhibitor, manumycin A (5 mg/kg body weight dissolved in 0.4% dimethyl sulfoxide, phosphate-buffered saline, subcutaneously 3 times per week; Sigma, St. Louis, Mo), or vehicle alone was commenced at 7 weeks of age in apoE-deficient mice fed a high-fat diet. The treatment with manumycin A was continued for 22 weeks. Then, after overnight fasting, blood samples were obtained to measure plasma cholesterol with a commercial kit (Sigma).
Analysis of Fatty Streak Lesion and Smooth Muscle-Like Cells in Neointima
After the 22-week treatment, fatty streak lesion at the aortic sinus was evaluated in apoE-deficient mice. The -smooth muscle actin expression was examined by immunohistochemistry and immunoblotting. For further details, see the supplemental information (available at http://atvb.ahajournls.org).
Detection of Superoxide Generation
Superoxide generation was evaluated by dihydroethidium labeling. For further details, see the supplemental information.
Detection of Tyrosine-Nitrated Proteins
Tyrosine-nitrated proteins were detected by immunohistochemistry23 and immunoblotting. For further details, see the supplemental information.
Determination of Activation Status of Ras
The aorta of apoE-deficient and age-matched wild-type C57BL/6 mice was homogenized as described previously.24 The abundance of Ras, Raf-1, and phosphorylated Raf-1 was determined by immunoblot analysis with anti-Pan-Ras (EMD Biosciences, San Diego, Calif), Raf-1 (Upstate, Lake Placid, NY), and phosphorylated Raf-1 (Cell Signaling, Beverly, Mass). Immunoblotting was performed as previously described.25 For a more detailed description of determination of the activation status of Ras, particularly evaluation of active GTP-bound Ras and farnesylated Ras, see the supplemental information.
Statistical Analysis
The data were compared using 1-way ANOVA followed by Fisher protected least significant difference test. A value of P<0.05 was considered statistically significant. All values were expressed as means±SEM.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Manumycin A Treatment Decreased Activation of Ras Pathway in the Aorta of ApoE-Deficient Mice
The treatment with farnesyltransferase inhibitor, manumycin A (5 mg/kg body weight, subcutaneously, 3 times per week), for 22 weeks did not affect plasma total cholesterol level (360±34.7, 399±46.8 mg/dL in vehicle- and manumycin A-treated animals, respectively), food intake (2.76±0.20, 2.53±0.05 g/d in vehicle- and manumycin A-treated animals, respectively), and body weight gain (vehicle: 23.0±0.5, 32.9±1.2, 33.0±1.4 g; and manumycin A: 23.2±0.4, 32.4±1.2, 33.2±2.0 at 0, 10 and 22 weeks after inception of the treatment, respectively).
To examine the effects of manumycin A on the activation status of Ras in the aorta of apoE-deficient mice, we evaluated active GTP-bound Ras, farnesylated Ras, and phosphorylation (activation) of Raf-1, an immediate downstream signaling molecule of Ras. Active Ras, farnesylated Ras, and phosphorylated Raf-1 were significantly increased in the aorta of vehicle-treated apoE-deficient mice compared with wild-type mice. Manumycin A treatment reverted increased active Ras, farnesylated Ras, and phosphorylated Raf-1 in apoE-deficient mice (Figure 1A, 1C, 1D). The abundance of total Ras and Raf-1 proteins did not differ between wild-type mice, and manumycin A- and vehicle-treated apoE-deficient mice (Figure 1B, 1E). These results clearly indicate that manumycin A decreased the activity of the Ras pathway in apoE-deficient mice, which was elevated relative to wild-type mice.
|
Manumycin A Treatment Reduced Fatty Streak Lesion Size in ApoE-Deficient Mice
We examined the effects of manumycin A on fatty streak lesion at the aortic sinus, a hallmark for early development of atherosclerosis. In vehicle-treated apoE-deficient mice, robust oil red O-positive lesion was observed at the aortic sinus. However, the fatty streak lesion size in manumycin A-treated apoE-deficient mice was significantly reduced to 43% of that observed in vehicle-treated apoE-deficient mice (P<0.05; Figure 2). In the aorta of wild-type mice, neither fatty streak lesion nor neointima was observed (data not shown).
|
Manumycin A Reduced Vascular Smooth Muscle-Like Cells in the Neointima in ApoE-Deficient Mice
Next, we examined the effects of farnesyltransferase inhibitor on the increase in vascular smooth muscle-like cells in neointima, a pathognomonic feature of the progression of mature atherosclerosis. In vehicle-treated apoE-deficient mice, -smooth muscle actin-positive area was prominent in the neointima as well as in the media. However, -smooth muscle actin-positive area in the neointima in manumycin A-treated apoE-deficient mice was diminished in size to 29% of that observed in vehicle-treated apoE-deficient mice (P<0.01; Figure 3A, 3B). In contrast, the extent of -smooth muscle actin immunoreactivity was similar in the media of both manumycin A- and vehicle-treated animals. Immunoblot analysis also demonstrated reduced expression of -smooth muscle actin by manumycin A, as compared with vehicle (Figure 3C), while β-actin expression was unaltered (Figure 3D).
|
Manumycin A Ameliorated Oxidative Stress in the Aorta of ApoE-Deficient Mice
The prevention of atherosclerosis development by manumycin A was accompanied by the amelioration of oxidative stress in apoE-deficient mice. In vehicle-treated apoE-deficient mice, substantial ex vivo superoxide generation was observed in the neointima. The incubation with Mn (II) TMPyP, a cell-permeable superoxide dismutase-mimetic, abolished ex vivo superoxide-derived signal, indicating the specificity of detection of superoxide. Manumycin A treatment significantly reduced ex vivo superoxide generation as compared with vehicle-treated apoE-deficient mice (Figure 4). The mitigation of oxidative stress by manumycin A was corroborated by immunohistochemical analysis with anti-nitrotyrosine antibody. In manumycin A-treated apoE-deficient mice, the immunoreactivity for nitrotyrosine, a surrogate marker for oxidative stress, was significantly reduced compared with vehicle-treated apoE-deficient mice (Figure 5A). Decreased tyrosine nitration by manumycin A was further confirmed by immunoblot analysis (Figure 5B). Tyrosine-nitrated proteins were increased in the aorta of vehicle-treated apoE-deficient mice compared with wild-type mice. Manumycin A treatment reduced tyrosine-nitrated proteins in apoE-deficient mice, although manumycin A did not fully reverse it to the level in wild-type mice. However, β-actin expression did not differ between the groups. Incubation with sodium dithionite (100 mmol/L) for 1 hour, which reduces nitrotyrosine to aminotyrosine,26 and prevented the immunostaining and immunoblotting with anti-nitrotyrosine antibody (supplemental Figures I and II, available online at http://atvb. ahajournals.org), indicating the specificity of the detection of nitrotyrosine.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We found that the treatment with farnesyltransferase inhibitor, manumycin A, reduced fatty streak lesion size and the area of vascular smooth muscle-like cells in the neointima in the aorta of apoE-deficient mice fed a high-fat diet without altering plasma cholesterol level (Figures 2 and 3
). The prevention of the development of atherosclerosis was accompanied by the amelioration of oxidative stress in apoE-deficient mice (Figures 4 and 5). These data indicate that the inhibition of farnesyltransferase prevents accumulation of lipid-laden macrophages and proliferation and/or migration of smooth muscle-like cells in the neointima, and also reduces oxidative stress in the aorta of apoE-deficient mice fed a high-fat diet. The reduction of farnesylated Ras, active Ras, and phosphorylated Raf-1 by manumycin A (Figure 1) indicates that manumycin A treatment effectively reduced farnesylation and activation of the Ras pathway, as expected. Consistent with previous studies,27,28 oxidative stress and activation of the Ras pathway were elevated in vehicle-treated apoE-deficient mice relative to wild-type mice. Previous studies have shown that pharmacological inhibition of farnesyltransferase by manumycin A,29 or FFT-277,30 or transfection of dominant-negative mutant of this enzyme31 inhibits proliferation, migration, and superoxide production in cultured vascular smooth muscle cells. Previous studies showed that the gene transfer of dominant negative mutant of Ras to vasculature suppressed intimal thickness induced by carotid artery injury in vivo.32,33 Taken together, the direct effects of manumycin A in vasculature is assumed to contribute to the protective effects of the farnesyltransferase inhibitor in the aorta of apoE-deficient mice.
A body of work in animal models and in cultured cells indicates an important contributory role for oxidative stress in atherogenesis.34–36 Antioxidants attenuated fatty streak lesion in apoE-deficient mice34,35 and hypercholesterolemic rabbits. Reactive oxygen species are involved in activation of macrophages, and proliferation, migration, and dedifferentiation of vascular smooth muscle cells.37,38 Therefore, it is reasonably conceivable that the amelioration of oxidative stress by manumycin A may contribute to the reduction of fatty streak lesion and smooth muscle-like cell accumulation in the neointima.
Farnesyltransferase inhibitors have been shown to exert cytostatic or proapoptotic effects in cultured cells, and the clinical trials are underway to evaluate its efficacy to treat the patients with cancer or leukemia.39 Inhibition of the Ras pathway is considered to play an important role in the anti-cancer activity of farnesyltransferase inhibitors. Of interest, NAD(P)H oxidase-mediated superoxide production is required for oncogenic Ras-induced transformation,40 and farnesyltransferase inhibitors reduce reactive oxygen species generation in transformed cells. Likewise, farnesyltransferase inhibitor FTI-227 blocked NAD(P)H oxidase-mediated superoxide generation induced by IL-1β, platelet-derived growth factor, or constitutively active mutant H-Ras in vascular smooth muscle cells.30 In contrast, Rac1, a major regulator of NAD(P)H oxidase activity, is not a direct target of farnesyltransferase inhibitor, because Rac1 is activated by geranylgeranylation, but not by farnesylation.41 It is reasonably conceivable, therefore, that decreased activity of the Ras pathway by manumycin A may mediate the amelioration of oxidative stress in the aorta of apoE-deficient mice.
However, oxidative stress also causes activation of the Ras pathway in various cell types including vascular smooth muscle cells.42,43 Hence, it is possible that reduced oxidative stress may also contribute to decreased activation of the Ras pathway in manumycin A-treated apoE-deficient mice. Based on the reciprocal relationship between these 2 signaling cascades, one can reasonably speculate that positive feedback loop between oxidative stress and activation of the Ras pathway may be formed in the disease conditions associated with atherogenesis, and that farnesyltransferase inhibition might prevent atherogenesis by blocking this vicious cycle.
Our data seem to be in accord with a previous study by George et al,27 showing that a selective inhibitor for Ras, farnesyl thiosalicylic acid, attenuated fatty streak lesion in apoE-deficient mice. However, the differences also appear to exist in the effects of farnesyl thiosalicylic acid and manumycin A. In the study of George et al,27 whereas 6-week treatment with this agent was associated with marked attenuation (52% reduction) in fatty streak lesion size, the effects of 10-week treatment with farnesyl thiosalicylic acid was less pronounced (28% reduction). These data seem to indicate that functional inhibition of Ras by farnesyl thiosalicylic acid might be more effective on early atherogenesis compared with mature atherosclerosis. In contrast, we found that 22-week treatment with farnesyltransferase inhibitor, manumycin A, reduced mature atherosclerosis, resulting in 57% and 71% reduction in fatty streak lesion size and -smooth muscle actin-positive area, respectively. Although the major substrates of farnesyltransferase are Ras family small G-proteins, other proteins such as RhoB, nuclear lamins, and some protein tyrosine phosphatases are also the targets for farnesyltransferase.44 Thus, the apparent difference in the effects of Ras inhibitor, farnesyl thiosalicylic acid, and farnesyltransferase inhibitor, manumycin A, could be explained by the effects of manumycin A on other substrates of farnesyltransferase than Ras. However, further studies will be required to clarify this point.
Because dimethyl sulfoxide is a hydroxyl radical scavenger, we cannot exclude the possibility that the injection of dimethyl sulfoxide itself might exert a beneficial effect. However, our preliminary observation revealed that administration of vehicle containing dimethyl sulfoxide by itself did not affect fatty streak lesion size at the aortic sinus in apoE-deficient mice on a high-fat diet (unpublished observation, M. Kaneki, 2005). It is important to note that the same dose of dimethyl sulfoxide was administered to both manumycin A- and vehicle-treated animals.
A potential contributory role of infection, particularly, that of Chlamydia pneumoniae, in atherosclerosis has been suggested. One can speculate, therefore, that antibiotic property of manumycin A might also contribute to the beneficial effects of manumycin A. However, previous studies and our observations do not appear to support this possibility. In apoE-deficient mice, it remains controversial whether C. pneumoniae accelerates atherogenesis.45,46 Antibiotics failed to ameliorate atherosclerosis in apoE-deficient mice.47,48 Moreover, antibacterial and antifungal activities of manumycin A are modest,49 although manumycin A is a potent farnesyltransferase inhibitor.50 We found that manumycin A did reduce farnesylated Ras (Figure 1C). Collectively, it seems unlikely that the protective effects of manumycin A might be substantially attributed to antibiotic activity rather than inhibition of farnesyltransferase.
In summary, farnesyltransferase inhibitor, manumycin A, significantly inhibited the development of mature atherosclerosis and reduced oxidative stress in the aorta of apoE-deficient mice. The present study suggests the possibility that inhibition of farnesylation may be involved in lipid-lowering–independent beneficial effects of statins. However, it remains to be clarified whether the concentrations of statins in human vasculature are really high enough to inhibit farnesylation in situ. The present data highlight farnesyltransferase as a potential molecular target to prevent the progression of atherosclerosis.
|
Acknowledgments |
|---|
We thank Dr J. Avruch for helpful discussion.
Sources of Funding
This work was supported by National Institutes of Health grant, R01DK058127 (M.K.).
Disclosures
None.
|
Footnotes |
|---|
Original received December 1, 2005; final version accepted February 7, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005–2016.[CrossRef][Medline] [Order article via Infotrieve]
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495–1504.
3. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003; 99: 95–112.[CrossRef][Medline] [Order article via Infotrieve]
4. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21: 1712–1719.
5. Bedi A, Flaker GC. How do HMG-CoA reductase inhibitors prevent stroke? Am J Cardiovasc Drugs. 2002; 2: 7–14.[CrossRef][Medline] [Order article via Infotrieve]
6. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev. 2003; 2: 332–338.[CrossRef][Medline] [Order article via Infotrieve]
7. Pierre-Paul D, Gahtan V. Noncholesterol-lowering effects of statins. Vasc Endovascular Surg. 2003; 37: 301–313.
8. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001; 37: 1450–1457.
9. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002; 54: 395–399.[CrossRef][Medline] [Order article via Infotrieve]
10. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol. 2000; 36: 410–416.
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004; 24: e149–161.
12. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001; 154: 87–96.[CrossRef][Medline] [Order article via Infotrieve]
13. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects–the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis. 2001; 155: 347–357.[CrossRef][Medline] [Order article via Infotrieve]
14. Mitani H, Egashira K, Kimura M. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol Res. 2003; 48: 417–427.[CrossRef][Medline] [Order article via Infotrieve]
15. Bandoh T, Mitani H, Niihashi M, Kusumi Y, Kimura M, Ishikawa J, Totsuka T, Sakurai I, Hayashi S. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol. 2000; 35: 136–144.[CrossRef][Medline] [Order article via Infotrieve]
16. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003; 108: 1368–1374.
17. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation. 2003; 108: 2113–2120.
18. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002; 22: 1452–1458.
19. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003; 108: 1560–1566.
20. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108: 426–431.
21. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther. 1997; 281: 1144–1153.
22. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001; 59: 646–654.
23. Fujimoto M, Shimizu N, Kunii K, Martyn JA, Ueki K, Kaneki M. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes. 2005; 54: 1340–1348.
24. Sugita H, Kaneki M, Tokunaga E, Sugita M, Koike C, Yasuhara S, Tompkins RG, Martyn JA. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab. 2002; 282: E386–E394.
25. Yasukawa T, Tokunaga E, Ota H, Sugita H, Martyn JA, Kaneki M. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem. 2005; 280: 7511–7518.
26. Ogino K, Nakajima M, Kodama N, Kubo M, Kimura S, Nagase H, Nakamura H. Immunohistochemical artifact for nitrotyrosine in eosinophils or eosinophil containing tissue. Free Radic Res. 2002; 36: 1163–1170.[CrossRef][Medline] [Order article via Infotrieve]
27. George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, Kloog Y, Keren G. Functional inhibition of Ras by S-trans, trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation. 2002; 105: 2416–2422.
28. Li YS, Shyy JY, Li S, Lee J, Su B, Karin M, Chien S. The Ras-JNK pathway is involved in shear-induced gene expression. Mol Cell Biol. 1996; 16: 5947–5954.[Abstract]
29. Kouchi H, Nakamura K, Fushimi K, Sakaguchi M, Miyazaki M, Ohe T, Namba M. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1999; 264: 915–920.[CrossRef][Medline] [Order article via Infotrieve]
30. Boota A, Johnson B, Lee KL, Blaskovich MA, Liu SX, Kagan VE, Hamilton A, Pitt B, Sebti SM, Davies P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2000; 278: L329–L334.
31. Solomon CS, Goalstone ML. Dominant negative farnesyltransferase alpha-subunit inhibits insulin mitogenic effects. Biochem Biophys Res Commun. 2001; 285: 161–166.[CrossRef][Medline] [Order article via Infotrieve]
32. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995; 1: 541–545.[CrossRef][Medline] [Order article via Infotrieve]
33. Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol. 1997; 17: 898–904.
34. Thomas SR, Leichtweis SB, Pettersson K, Croft KD, Mori TA, Brown AJ, Stocker R. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. 2001; 21: 585–593.
35. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med. 1998; 4: 1189–1192.[CrossRef][Medline] [Order article via Infotrieve]
36. Cyrus T, Yao Y, Rokach J, Tang LX, Pratico D. Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation. 2003; 107: 521–523.
37. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med. 1998; 132: 9–15.[CrossRef][Medline] [Order article via Infotrieve]
38. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 23–28.
39. Mazieres J, Pradines A, Favre G. Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett. 2004; 206: 159–167.[CrossRef][Medline] [Order article via Infotrieve]
40. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997; 275: 1649–1652.
41. Kinsella BT, Erdman RA, Maltese WA. Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J Biol Chem. 1991; 266: 9786–9794.
42. Yamakawa T, Tanaka S, Yamakawa Y, Kamei J, Numaguchi K, Motley ED, Inagami T, Eguchi S. Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2002; 22: 752–758.
43. Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, Cohen RA. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem. 2004; 279: 29857–29862.
44. Johnston SR. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol. 2001; 2: 18–26.[CrossRef][Medline] [Order article via Infotrieve]
45. Aalto-Setala K, Laitinen K, Erkkila L, Leinonen M, Jauhiainen M, Ehnholm C, Tamminen M, Puolakkainen M, Penttila I, Saikku P. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 578–584.
46. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation. 2001; 103: 2834–2838.
47. Rothstein NM, Quinn TC, Madico G, Gaydos CA, Lowenstein CJ. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis. 2001; 183: 232–238.[CrossRef][Medline] [Order article via Infotrieve]
48. Blessing E, Campbell LA, Rosenfeld ME, Chesebro B, Kuo CC. A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae. J Antimicrob Chemother. 2005; 55: 1037–1040.
49. Sattler I, Thiericke R, Zeeck A. The manumycin-group metabolites. Nat Prod Rep. 1998; 15: 221–240.[CrossRef][Medline] [Order article via Infotrieve]
50. Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. J Cell Biochem Suppl. 1997; 27: 12–19.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  B. C. Capell, M. Olive, M. R. Erdos, K. Cao, D. A. Faddah, U. L. Tavarez, K. N. Conneely, X. Qu, H. San, S. K. Ganesh, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model PNAS, October 14, 2008; 105(41): 15902 - 15907. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||